DHM (Di-Hydro Mitragynine): The 7-OH Alternative Explained

What Is DHM (Di-Hydro Mitragynine)?

Di-Hydro Mitragynine — abbreviated DHM, sometimes labeled MGM-15 — is a semi-synthetic derivative of mitragynine, the primary alkaloid in kratom (Mitragyna speciosa). To produce it, chemists add hydrogen across a specific double bond on the mitragynine molecule, a process called hydrogenation. The result is a structurally similar but chemically distinct compound with a different receptor interaction profile.

It is not a naturally dominant alkaloid. Mitragynine itself is — it accounts for roughly 60–70% of the alkaloid content in most kratom strains. DHM is intentionally produced through controlled modification of that parent compound, which is why it can be standardized, dosed precisely, and marketed separately from full-spectrum kratom products.

Where DHM Fits in the Kratom Alkaloid Family

To understand DHM, you need to see where it sits relative to the two alkaloids most people already know.

Mitragynine — The Baseline

Mitragynine is the main active alkaloid in kratom. It acts as a partial agonist at mu-opioid receptors (MOR) and also interacts with adrenergic and serotonergic systems. At low doses it produces stimulant-like effects; at higher doses more sedating and analgesic properties emerge. A portion of mitragynine metabolizes into 7-hydroxymitragynine in the body — and that conversion contributes significantly to kratom's stronger effects.

7-Hydroxymitragynine (7-OH) — High Potency, High Scrutiny

7-OH is a minor alkaloid in raw kratom leaf but has significantly higher potency at opioid receptors than mitragynine. It binds with much stronger affinity to the MOR, producing more pronounced analgesia, sedation, and euphoria — and carrying a meaningfully higher dependency and abuse risk. That potency is exactly why 7-OH has become a regulatory target. Several states and localities have restricted or banned it outright, creating demand for alternatives that work through related but different pathways.

DHM / Dihydromitragynine (MGM-15) — The Middle Path

DHM sits between baseline mitragynine and high-potency 7-OH — but it is distinct from both. Three differences define it:

• No 7-OH conversion pathway. Unlike standard mitragynine, dihydromitragynine does not convert to 7-OH in the body (or does so to a negligible degree). This is why it can be marketed as "0% 7-OH" and sold in markets where 7-OH is restricted.
• Weaker MOR activity. DHM still interacts with opioid receptors, but at lower intensity than either mitragynine at peak or 7-OH.
• Possible shift toward adrenergic signaling. DHM's modified structure appears to shift more of its receptor activity toward non-opioid systems — which may explain the "cleaner" and more "functional" quality users often describe.

The Chemistry, Simplified

Mitragynine contains a specific double bond in its molecular structure. Hydrogenation — adding hydrogen across that bond — saturates it. The result is dihydromitragynine. The indole-based backbone remains intact, but the change in three-dimensional shape and lipophilicity alters how the molecule fits into and activates opioid receptors.

Think of it like reshaping a key slightly. It still fits in the same lock, but it doesn't turn as far — and it doesn't unlock the adjoining room (7-OH's metabolic pathway) at all.

Effects Profile: What Users Report

There is very little formal clinical research on dihydromitragynine. The following reflects user-reported experience and is not a substitute for medical guidance.

Compared to Mitragynine

• Less euphoria
• Less sedation
• Shorter or flatter peak effect
• More "clear-headed" and "functional"
• Better suited for daytime use

Compared to 7-OH

• Significantly weaker analgesia
• Lower opioid-like intensity
• Less "body load" or heaviness
• Minimal "rush" or reinforcement

Commonly Reported Effects

• Mild mood lift
• Light pain relief
• Subtle stimulation at lower doses
• Minimal sedation

Why DHM Is Gaining Traction

Regulatory Positioning

In states and localities that have restricted or banned 7-OH, DHM occupies a different legal position. Because it doesn't share 7-OH's chemical identity and doesn't produce it in vivo, it falls outside those specific restrictions in many jurisdictions. It is not currently regulated at the federal level — though local laws vary significantly. Always verify your local regulations before purchasing.

Retail Practicality

For retailers operating in markets with increasing scrutiny on kratom-adjacent products, a verified "0% 7-OH" SKU is a meaningful compliance differentiator. DHM can often be stocked and sold in markets where 7-OH cannot.

Tolerance Management

Some regular kratom users rotate to DHM as part of a step-down or tolerance-reset strategy — using a lower-intensity alkaloid to reduce reliance on stronger products without stopping entirely. This is self-reported behavior and is not a medically endorsed protocol.

Hazards and Reality Check

DHM being positioned as a "softer" alternative to 7-OH doesn't mean it's without risk. Here's what you need to know honestly:

• It still interacts with opioid receptors. DHM is not a traditional herbal supplement. It acts on the same receptor systems as opioids, even if at lower potency.
• Dependency risk is not well established. Claims that DHM has lower addiction potential than 7-OH are largely marketing-driven. There is no robust clinical data confirming its long-term safety or dependency profile.
• Very limited research exists. MGM-15/dihydromitragynine has not been through clinical trials. Its pharmacokinetics, long-term effects, and drug interaction profile are not comprehensively understood.
• Dose matters. Effects are dose-dependent. Using more to compensate for lower potency carries serious risks.
• Not for everyone. DHM is not appropriate for pregnant or nursing women, individuals using opioid medications or CNS depressants, or those with a history of opioid use disorder. Consult a physician before use.

The bottom line: "different" does not automatically mean "safer." Treat DHM with the same caution and respect you'd give any opioid-adjacent compound.

Naked DHM 20mg Tablets

Our DHM tablets deliver 20mg of Di-Hydro Mitragynine per tablet, pressed from high-quality plant material and tested for identity, purity, and potency. Each batch comes with a Certificate of Analysis verifying microbial safety, moisture content, and alkaloid consistency.

Available in single tablets, 3-count pouches, and 10-count bottles — built for on-the-go use with precise, reliable dosing every time.

Start with ½ tablet or less to assess tolerance. Do not exceed 3 tablets per week.

Shop Naked DHM 20mg Tablets →

The Bottom Line

DHM (Di-Hydro Mitragynine) represents a real — but still poorly-studied — position in the kratom alkaloid landscape. It's chemically distinct from 7-OH, bypasses its metabolic pathway, and is generally reported to produce a milder, more functional experience. That makes it genuinely useful as a 7-OH alternative in restricted markets. But "different" isn't the same as "proven safe." Use responsibly, stay within recommended limits, and stay informed as research on these compounds continues to develop.